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We appreciate the interest by Jarai and colleagues in our
recent paper (1). Unfortunately, from the FRISC-II data we
cannot answer the questions raised. Further subgrouping of
the data makes the groups small and estimates unreliable.
A number of problems arise when trying to define
optimal decision limits in patients with non–ST-segment
elevation acute coronary syndrome. One problem is that the
level of N-terminal pro-brain natriuretic peptide (NT-
proBNP) changes over time after presentation. Previous
studies have shown that the level of NT-proBNP increases
during the first 14 to 48 h after a myocardial infarction (2),
and thereby gradually decreases at least for six months (3).
Therefore, the timing in relation to the acute event will be
important when defining optimal decision limits for NT-
proBNP in patients with non–ST-segment elevation acute
coronary syndromes. Thus, NT-proBNP levels measured
after a median time of 9 h from the last episode of
symptoms in the GUSTO-IV trial (4) does not correspond
to levels measured after a median time of 39 h in the
FRISC-II trial (1).
Another important issue is whether decision limits should
be related to gender. It is well known that NT-proBNP
levels are higher in women (5). The reason for this gender-
related difference is still unclear. The fact that the age-
related mortality is lower in women than in men suggests
that the reason for this gender difference does not cause
increased mortality. Therefore, we believe gender differ-
ences should be considered when determining suitable
decision limits. Evidently, further studies regarding the best
time point for analysis and the most appropriate decision
limit are needed.
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Troponin and Outcomes
We read with interest the report of Kontos et al. (1), which
showed that any detectable troponin I in the serum of
patients admitted with chest pain was associated with worse
outcomes. We recently reported the results of a similar study
involving troponin T levels (2), and we found that among
428 patients admitted with ongoing chest pain, troponin T
levels that were detectable but within the range reported as
normal were markers of an increased risk of death/
subsequent myocardial infarction/revascularization during
the four-month follow-up.
We would like to comment on two aspects of the Kontos
et al. (1) study: 1) the conclusion that most of the tests with
detectable cardiac troponin I in the normal range “represent
analytical false positive results due to the assays themselves”
and 2) what to call detectable troponin values within the
normal range. Troponin assays are exquisitely sensitive and,
conceptually, a minor event, that cannot be detected clini-
cally, can lead to a detectable level of troponin in the serum.
Instead of thinking of detectable levels of troponin in
patients with a negative subsequent workup as “false posi-
tive,” we believe that the patients should be thought of as
having suffered a minor event, be it transient vascular
occlusion, blood pressure changes, short runs of ventricular
arrhythmias, or any number of other conditions (3).
Whereas most patients suffer no testable harm from such
events, some do, and hence the observed higher risk of poor
outcomes.
Finally, in our report we referred to detectable troponin
within the normal range as “marginal” troponin, indicative
of “minor myocardial injury.” We believe these terms aid in
thinking about these patients, and we would advocate their
continued use.
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REPLY
We appreciate the interest by Drs. Henrikson and Chandra-
Strobos in our recent study (1). They disagree with the
conclusion that lower levels of troponin are likely analytical
false positives and are more likely related to necrosis. This is
based on the results of their recent study (2), in which
patients with minor troponin T (TnT) elevations had a
higher event than those without detectable levels, and were
closer to those with clearly elevated levels (2).
However, the two studies are not directly comparable.
The range of TnT levels, which they called “marginal”
(defined as levels between 0.01 ng/ml and 0.09 ng/ml), was
fairly broad. The TnT levels from 0.01 to 0.03 ng/ml
(between the lower limit of detectability and 10% coefficient
of variation [CV]) (3) are equivalent to our low troponin I
values, whereas those from 0.03 to 0.09 ng/ml (from the
10% CV to the prior myocardial infarction [MI] diagnostic
criteria) would be equivalent to our intermediate TnI levels.
The fact that their marginal TnT values are a combination
of low and intermediate TnT values likely explains the
higher event rate that was found. For example, the propor-
tion of patients who had elevated creatine kinase-MB
fraction (CK-MB) was 15% in our TnI intermediate group,
comparable to 14% in their marginal TnT group; in
contrast, only 1.1% of patients in our TnI low group had
increased CK-MB.
In addition, we did not call patients with detectable TnI
values “normal.” We made the distinction between low
elevations, in which some represent necrosis; this is seen by
the higher event rate. However, as we and others have noted
(4), this is a mixture of a small number of patients who truly
have necrosis and a much higher number who have analyt-
ical false positives. As we noted, labeling a patient who has
atypical chest pain, no-ischemic electrocardiographic
changes, low levels of CK-MB not near the diagnostic
cut-off, and with minor troponin elevations as having an
myocardial infarction has significant implications for the
patient’s long-term health care, and we believe this is
inappropriate. As none of the currently available assays
conform to recommended standards (5), our data, as well as
other recommendations (6), are that these values may be
indicative of necrosis, and therefore should be further
evaluated. This evaluation should be dependent on the
clinical scenario. Rather than routinely performing coronary
angiography as recommended by the American College of
Cardiology/American Heart Association guidelines for pa-
tients who have troponin elevations, we believe that stress
testing would be an appropriate evaluation, for many of
these patients.
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The Diet–Heart Hypothesis:
An Evolutionary Support
Nothing in biology makes sense except in the light of evolution.
Theodosius Dobzhansky, 1973
Considering that humankind and its metabolic physiology
are biological products of evolution, one might well ask why
Weinberg’s report (1) not only ignores the evolutionary
arguments supporting the diet–heart hypothesis, but also
advances the evolutionarily untenable thesis that the low-
fat, high-carbohydrate diet is responsible for the current
epidemics of obesity, type II diabetes, and the metabolic
syndrome.
Weinberg seems to forget that the low-fat, high-
carbohydrate diet represents the diet “for which human
beings are in essence genetically programmed” (2), because
their metabolic physiology has been evolutionarily molded
by a nutritional environment in which, for millions of years,
that diet was practically the sole one available to our
ancestors (3). For 99% of its evolution, humankind indeed
lived mainly on fruits and vegetables, which consist essen-
tially of carbohydrates, and consumed little fat, because
game was very lean and cattle-breeding, chicken farming,
butter, dairy products, margarines, and oils did not exist (2).
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